Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Geert R. DʼHaens, Remo Panaccione, Filip Baert, et al.
The Lancet (2022) Vol. 399, Iss. 10340, pp. 2015-2030
Closed Access | Times Cited: 257

Showing 1-25 of 257 citing articles:

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Marc Ferrante, Remo Panaccione, Filip Baert, et al.
The Lancet (2022) Vol. 399, Iss. 10340, pp. 2031-2046
Closed Access | Times Cited: 208
Crohn's disease
Michael Dolinger, Joana Torres, Séverine Vermeire
The Lancet (2024) Vol. 403, Iss. 10432, pp. 1177-1191
Closed Access | Times Cited: 114
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Bram Verstockt, Azucena Salas, Bruce E. Sands, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 102
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis
Brigida Barberio, David J. Gracie, Christopher J. Black, et al.
Gut (2022) Vol. 72, Iss. 2, pp. 264-274
Open Access | Times Cited: 100
Strategies for targeting cytokines in inflammatory bowel disease
Markus F. Neurath
Nature reviews. Immunology (2024) Vol. 24, Iss. 8, pp. 559-576
Closed Access | Times Cited: 85
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 61
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
Improving IBD outcomes in the era of many treatment options
Taku Kobayashi, Toshifumi Hibi∥
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 2, pp. 79-80
Open Access | Times Cited: 56
Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing
Markus F. Neurath, Michael Vieth
Gut (2023) Vol. 72, Iss. 11, pp. 2164-2183
Closed Access | Times Cited: 54
The role of inflammation in autoimmune disease: a therapeutic target
Yu Xiang, Mingxue Zhang, D.Y. Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 52
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin, et al.
Gastroenterology (2023) Vol. 165, Iss. 6, pp. 1443-1457
Open Access | Times Cited: 47
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
Laurent Peyrin‐Biroulet, J. Casey Chapman, Jean‐Frédéric Colombel, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 3, pp. 213-223
Closed Access | Times Cited: 39
Risankizumab for Ulcerative Colitis
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
JAMA (2024) Vol. 332, Iss. 11, pp. 881-881
Closed Access | Times Cited: 25
Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis
James Yarmolinsky, Jamie Robinson, Daniela Mariosa, et al.
EBioMedicine (2024) Vol. 100, pp. 104991-104991
Open Access | Times Cited: 22
Heavy arch: from inflammatory bowel diseases to metabolic disorders
Timon E. Adolph, Moritz Meyer, A Jukic, et al.
Gut (2024) Vol. 73, Iss. 8, pp. 1376-1387
Open Access | Times Cited: 18
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
James G. Krueger, Kilian Eyerich, Vijay K. Kuchroo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 17
Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 16
Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 4
Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease
Shahida Din, Christian P. Selinger, Christopher J. Black, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 6, pp. 666-675
Open Access | Times Cited: 44
Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review
Yasmin Zurba, Beatriz Gros, Mohammad Shehab
Biomedicines (2023) Vol. 11, Iss. 3, pp. 747-747
Open Access | Times Cited: 39
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial
Alexa B. Kimball, Errol P. Prens, Thierry Passeron, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 5, pp. 1099-1111
Open Access | Times Cited: 38
Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
Elisabetta Bretto, Davide Giuseppe Ribaldone, Gian Paolo Caviglia, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2249-2249
Open Access | Times Cited: 35
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
Jean‐Frédéric Colombel, Ryan C. Ungaro, Bruce E. Sands, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 7, pp. 1487-1496.e12
Open Access | Times Cited: 34
Targeting IL-23 for IBD: Rationale and Progress to Date
Sudheer K. Vuyyuru, Lisa M. Shackelton, Jurij Hanžel, et al.
Drugs (2023) Vol. 83, Iss. 10, pp. 873-891
Closed Access | Times Cited: 29
Mucosal healing and inflammatory bowel disease: Therapeutic implications and new targets
Megan Lynn Otte, Raju Lama Tamang, Julia Papapanagiotou, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 7, pp. 1157-1172
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top